Tags

Type your tag names separated by a space and hit enter

Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
J Clin Virol. 2022 06; 150-151:105161.JC

Abstract

BACKGROUND

Booster doses for COVID-19 vaccinations are currently recommended and approved in many countries. However, we need more evidence on the immune response of individuals to booster doses of inactivated vaccines and the neutralizing effect against the variants of concerns of SARS-CoV-2.

OBJECTIVE

To compare the fold reduction in antibody titers against the variants of concerns of SARS-CoV-2 between the primary doses and booster dose vaccine cohorts of inactivated BBIBP-CorV vaccine.

STUDY DESIGN

In this observational study Plaque Reduction Neutralization Test (PRNT) assay was done on pooled serum samples of the recipients of primary two doses of inactivated BBIBP-CorV and on the pooled serum samples of recipients of a booster dose of inactive BBIBP-CorV. The neutralizing antibody titers against the wild (Wuhan) strain and the variants of concern (alpha, beta and delta) were compared.

RESULTS

The serum sample pool from the booster cohort had high neutralizing antibody titers against the SARS-CoV-2 variants compared to the pooled serum samples of the recipients of primary two doses of inactivated BBIBP-CorV and the difference was statistically significant. The observed fold reduction in antibody titers from the serum pool of recipients of two doses of BBIBP-CorV vaccine were 3.7-fold, 14.6-fold and 10.4-fold compared to 1.8 -fold, 6.5-fold and 3.8-fold reduction against the alpha, beta and delta lineages respectively in the serum pool of recipient of a booster dose (three doses of BBIBP-CorV).

CONCLUSION

Booster doses of inactive BBIBP-CORV offered better protection against the variants of concern of SARS-CoV-2.

Links

PMC Free PDF

Authors+Show Affiliations

Mahmoud S
Biogenix labs, G42, Abu Dhabi, UAE. Electronic address: sally.mahmoud@g42.ai.
Ganesan S
G42 Healthcare, Abu Dhabi, UAE; IROS (Insights Research Organization & Solutions), Abu Dhabi, UAE. Electronic address: subhashini.g@g42.ai.
Al Kaabi N
Sheikh Khalifa Medical City, SEHA, Abu Dhabi, UAE; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE.
Naik S
Biogenix labs, G42, Abu Dhabi, UAE.
Elavalli S
G42 Healthcare, Abu Dhabi, UAE.
Gopinath P
Biogenix labs, G42, Abu Dhabi, UAE.
Ali AM
Biogenix labs, G42, Abu Dhabi, UAE.
Bazzi L
Biogenix labs, G42, Abu Dhabi, UAE.
Warren K
G42 Healthcare, Abu Dhabi, UAE.
Zaher WA
G42 Healthcare, Abu Dhabi, UAE; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE; IROS (Insights Research Organization & Solutions), Abu Dhabi, UAE; College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE.
Hosani FA
Abu Dhabi Public Health Center, Abu Dhabi, UAE.

MeSH

Antibodies, NeutralizingAntibodies, ViralCOVID-19HumansImmunitySARS-CoV-2Vaccines, Inactivated

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

35439702

Citation

Mahmoud, Sally, et al. "Immune Response of Booster Doses of BBIBP-CORV Vaccines Against the Variants of Concern of SARS-CoV-2." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 150-151, 2022, p. 105161.
Mahmoud S, Ganesan S, Al Kaabi N, et al. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. J Clin Virol. 2022;150-151:105161.
Mahmoud, S., Ganesan, S., Al Kaabi, N., Naik, S., Elavalli, S., Gopinath, P., Ali, A. M., Bazzi, L., Warren, K., Zaher, W. A., & Hosani, F. A. (2022). Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 150-151, 105161. https://doi.org/10.1016/j.jcv.2022.105161
Mahmoud S, et al. Immune Response of Booster Doses of BBIBP-CORV Vaccines Against the Variants of Concern of SARS-CoV-2. J Clin Virol. 2022;150-151:105161. PubMed PMID: 35439702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. AU - Mahmoud,Sally, AU - Ganesan,Subhashini, AU - Al Kaabi,Nawal, AU - Naik,Shivaraj, AU - Elavalli,Santosh, AU - Gopinath,Prem, AU - Ali,Alaa Mousa, AU - Bazzi,Lara, AU - Warren,Katherine, AU - Zaher,Walid Abbas, AU - Hosani,Farida Al, Y1 - 2022/04/12/ PY - 2021/12/28/received PY - 2022/04/05/revised PY - 2022/04/11/accepted PY - 2022/4/20/pubmed PY - 2022/5/20/medline PY - 2022/4/19/entrez KW - COVID-19 KW - Neutralizing antibodies KW - SARS-CoV-2 KW - booster dose KW - variants of concern SP - 105161 EP - 105161 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 150-151 N2 - BACKGROUND: Booster doses for COVID-19 vaccinations are currently recommended and approved in many countries. However, we need more evidence on the immune response of individuals to booster doses of inactivated vaccines and the neutralizing effect against the variants of concerns of SARS-CoV-2. OBJECTIVE: To compare the fold reduction in antibody titers against the variants of concerns of SARS-CoV-2 between the primary doses and booster dose vaccine cohorts of inactivated BBIBP-CorV vaccine. STUDY DESIGN: In this observational study Plaque Reduction Neutralization Test (PRNT) assay was done on pooled serum samples of the recipients of primary two doses of inactivated BBIBP-CorV and on the pooled serum samples of recipients of a booster dose of inactive BBIBP-CorV. The neutralizing antibody titers against the wild (Wuhan) strain and the variants of concern (alpha, beta and delta) were compared. RESULTS: The serum sample pool from the booster cohort had high neutralizing antibody titers against the SARS-CoV-2 variants compared to the pooled serum samples of the recipients of primary two doses of inactivated BBIBP-CorV and the difference was statistically significant. The observed fold reduction in antibody titers from the serum pool of recipients of two doses of BBIBP-CorV vaccine were 3.7-fold, 14.6-fold and 10.4-fold compared to 1.8 -fold, 6.5-fold and 3.8-fold reduction against the alpha, beta and delta lineages respectively in the serum pool of recipient of a booster dose (three doses of BBIBP-CorV). CONCLUSION: Booster doses of inactive BBIBP-CORV offered better protection against the variants of concern of SARS-CoV-2. SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/35439702/Immune_response_of_booster_doses_of_BBIBP_CORV_vaccines_against_the_variants_of_concern_of_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -